Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis

Thursday, January 29, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the effects of Seralutinib on endotrophin (PRO-C6) production, highlighting its potential to decrease this mediator of fibrosis and inflammation in an in vitro model of pulmonary fibrosis. This finding suggests that Seralutinib could be a promising candidate for treating pulmonary fibrosis. The results indicate a positive impact on managing fibrosis-related conditions.
Price reaction · baseline $2.55 (2026-01-28 close) · hit pre-market · 2 other GOSS headline(s) in the window, move may be shared
day 0 close
-5.1%
day 1 · peak
-10.6%
day 3
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib effectively reduces endotrophin production.
  • Demonstrates potential as a treatment for pulmonary fibrosis.
  • In vitro model shows promising results for fibrosis and inflammation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the effect of Seralutinib on endotrophin?

Seralutinib decreases endotrophin (PRO-C6) production, which is linked to fibrosis.

In what model was Seralutinib tested?

Seralutinib was tested in an in vitro model of pulmonary fibrosis.

What condition could Seralutinib potentially treat?

Seralutinib shows potential for treating pulmonary fibrosis.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary fibrosis endotrophin PRO-C6 in vitro
Last updated: Jan 29, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →